E Fund Pharmaceutical and Biotechnology Equity Securities Investment Fund (abbreviation: E Fund Pharmaceutical and Biotechnology Stock A, code 010387) announced its latest net value on March 27, up 5.74%.
E Fund Pharmaceutical and Biotechnology Stock A was established on November 4, 2020, and the performance comparison benchmark is the return rate of Shenwan Pharmaceutical and Biotechnology Industry Index ×70% + the return rate of CSI Hong Kong Stock Connect Medical and Health Composite Index ×15% + the return rate of China Bond Total Index ×15%. The fund has returned -31.47% since its inception, with a 15.53% return this year, a 5.19% return over the past month, a 13.74% return over the past year, and a 13.39% return over the last three years. In the past year, the fund ranked 2169/3480 in its peer group.
The fund managers are Yang Zhenxiao and Xu Zheng. Yang Zhenxiao has managed (or intends to manage) the fund since October 13, 2020, with a return of -31.47% during his tenure; Xu Zheng has managed (or intends to manage) the fund since March 7, 2023, with a return of 0.31% during his tenure.
According to the latest periodic report, the fund's top 10 heavy stocks are as follows:
| stock symbol | ,stock name | ,position ratio | , number of shares held (shares). | Market value of the position (RMB). |
| 600276 | Hengrui Pharmaceutical | 9.41% | 6411179 | 294 million |
| 688617 | Huitai Medical | 8.39% | 704318 | 262 million |
| 300347 | Tigermed | 8.25% | 4720405 | 258 million |
| 03692 | Hansoh Pharmaceuticals | 6.56% | 12820000 | 205 million |
| 300832 | New Industry | 6.31% | 2782778 | 197 million |
| 09926 | Akeso Bio | 5.79% | 3220905 | 181 million |
| 01801 | Innovent Biologics | 5.72% | 5274500 | 179 |
| million 688050 | Aibo Medical | 4.86% | 1670338 | 152 million |
| 06618 | JD Health | 4.82% | 5791250 | 151 million |
| 02162 | Connova-B | 4.68% | 5114500 | 146 million |
Ticker Name
Percentage Change
Inclusion Date
